Efgartigimod for Myasthenia Gravis- Phase 3

14 ม.ค. 2019

Those who have the ability to ignore the noise and the roller coaster ride that the markets have brought upon us from early October to this day, you would be +80% on ARGX. Nevertheless, if you were/are trading/playing it, it's a good play.

Whether it's politics or economics, there's way too many factors in play so all things are considered, -awareness for the win.

Biotech wise, there are only few variables that I need to ponder here. Short float is at 2.84% because a convincing phase3 data on ARGX-113 for Myasthenia Gravis, will blow the shorts. Not to mention Cusatuzumab for acute myeloid leukemia. These are just 2 of the many 2019 catalysts.

Other key stats: 1) 500mm from the Janssen deal -JNJ, 2) 10mm payment from Abbvie- (2018 preclinical milestone on ARGX-115), upon achievements of other milestones they're eligible for up to $625 million and double digit royalties upon commercialization.

Overweight on Morgan Stanley, Jan 4th, '19.
Buy on Goldman, Dec 17th, '18

Bottomline, I am watching this. You have to!

14 ม.ค. 2019

การซื้อขายยังคงดำเนินอยู่

Let's see.. I am long here at 103.47 on Jan 14th.

16 ม.ค. 2019

ปิดการเทรด ด้วยตนเอง

Closed. Will go in again later.

25 ก.พ. 2019

ปิดการเทรด: ถึงเป้าหมายการทำกำไร